Vivos Therapeutics completed a private placement (PIPE) totaling approximately $2.1 million through a Securities Purchase Agreement with V-Co Investors 4 and Bigger Capital Fund. The financing comprised 3,608,496 units at $0.582 per unit, each with one share of Series A Convertible Preferred Stock and a warrant exercisable at $0.456 per share. The company received $1.0 million in cash at closing, and $1.0 million previously funded under a bridge note converted into the PIPE. In connection with the financing, Vivos also entered into a Registration Rights Agreement obligating it to file a resale registration statement within 45 days and seek effectiveness within 90 days, maintaining effectiveness until the securities are freely tradable.
Agreement 1: Vivos Therapeutics Raises $2.1 Million in PIPE With V-Co 4 and Bigger Capital
- Agreement type: Securities Purchase Agreement for private placement (PIPE) of Units (Series A Preferred and Warrants)
- Counterparty: V-Co Investors 4; Bigger Capital Fund
- Signed / Effective: Jun 30 2026 / same
- Duration / Termination: At will
- Reason: Enhance liquidity and fund working capital
Agreement 2: Vivos Therapeutics Grants Resale Registration Rights to PIPE Investors
- Agreement type: Registration Rights Agreement for resale of conversion and warrant shares
- Counterparty: V-Co Investors 4; Bigger Capital Fund
- Signed / Effective: Jun 30 2026 / same
- Duration / Termination: Until all registrable securities are freely tradable
- Reason: Provide investor liquidity and facilitate resale
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.